Zobrazeno 1 - 10
of 33
pro vyhledávání: '"MESH: ras Proteins"'
Autor:
Kevin P. Claffey, Peter F. Johnson, Mesfin Gonit, Myriam Gorospe, Atharva Bhat, Jacqueline Salotti, Jiji Chen, Sandip K. Basu, Benoit Viollet
Publikováno v:
Oncogene
Oncogene, Nature Publishing Group, 2018, 37 (26), pp.3528-3548. ⟨10.1038/s41388-018-0190-7⟩
Oncogene, 2018, 37 (26), pp.3528-3548. ⟨10.1038/s41388-018-0190-7⟩
Oncogene, Nature Publishing Group, 2018, 37 (26), pp.3528-3548. ⟨10.1038/s41388-018-0190-7⟩
Oncogene, 2018, 37 (26), pp.3528-3548. ⟨10.1038/s41388-018-0190-7⟩
International audience; Oncogene-induced senescence (OIS) is an intrinsic tumor suppression mechanism that requires the p53 and RB pathways and post-translational activation of C/EBPβ through the RAS-ERK cascade. We previously reported that in trans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f96479720ffa7791b98f5a6d122dc7
https://pubmed.ncbi.nlm.nih.gov/29563610
https://pubmed.ncbi.nlm.nih.gov/29563610
Autor:
Vincent Denis, Christel Larbouret, Laetitia K. Linares, Esther Pérez-Gracia, Delphine Desigaud, Adeline Ayrolles-Torro, Nadia Vie, M. del Rio, Marta Jarlier, Clara Montagut, Diego Tosi, E W-F Lam, Laetitia Marzi, Mar Iglesias, Céline Gongora, Pierre Martineau, Eve Combes
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2016, 115 (10), pp.1223-1233. ⟨10.1038/bjc.2016.313⟩
British Journal of Cancer, Cancer Research UK, 2016, 115 (10), pp.1223-1233. ⟨10.1038/bjc.2016.313⟩
BACKGROUND: Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4579077d1c4aa1c4faf7dd0c8990a4d2
https://www.hal.inserm.fr/inserm-02465222
https://www.hal.inserm.fr/inserm-02465222
Autor:
Jean Claude Rousselle, Serge Pauillac, Jacques D'allayer, Pascal Lenormand, Philippe Bouvet, Michel R. Popoff
Publikováno v:
Toxicon
Toxicon, Elsevier, 2013, 75, pp.136-143. 〈10.1016/j.toxicon.2013.07.003〉
Toxicon, Elsevier, 2013, 75, pp.136-143. ⟨10.1016/j.toxicon.2013.07.003⟩
Toxicon, 2013, 75, pp.136-143. ⟨10.1016/j.toxicon.2013.07.003⟩
Toxicon, Elsevier, 2013, 75, pp.136-143. 〈10.1016/j.toxicon.2013.07.003〉
Toxicon, Elsevier, 2013, 75, pp.136-143. ⟨10.1016/j.toxicon.2013.07.003⟩
Toxicon, 2013, 75, pp.136-143. ⟨10.1016/j.toxicon.2013.07.003⟩
International audience; TpeL is a toxin produced by Clostridium perfringens which belongs to the large clostridial glucosylating toxin family. It was shown that TpeL modifies Ras using UDP-glucose or UDP-N-acetylglucosamine as cosubstrates (Guttenber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad082565c4fddaaf06ba5c7e5fb700b
https://hal-pasteur.archives-ouvertes.fr/pasteur-01766020
https://hal-pasteur.archives-ouvertes.fr/pasteur-01766020
Autor:
Raouf Ben Abdelali, Véronique Lhéritier, Jean-Yves Cahn, Françoise Huguet, Norbert Ifrah, Agnès Buzyn, Noémie de Gunzburg, Elizabeth Macintyre, Vahid Asnafi, Dominique Payet-Bornet, Sébastien Maury, Jonathan Bond, Thibaud Leguay, Amélie Trinquand, Bertrand Nadel, André Delannoy, Kheira Beldjord, Hervé Dombret, Xavier Thomas, Jérôme Lambert, Ludovic Lhermitte, Hossein Mossafa, Etienne Lengliné, Yves Chalandon, Caroline Bonmati, Aline Tanguy-Schmidt
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2013, 31 (34), pp.4333-42. 〈10.1200/JCO.2012.48.5292〉
Journal of Clinical Oncology, Vol. 31, No 34 (2013) pp. 4333-42
Journal of Clinical Oncology, 2013, 31 (34), pp.4333-42. ⟨10.1200/JCO.2012.48.5292⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2013, 31 (34), pp.4333-42. ⟨10.1200/JCO.2012.48.5292⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2013, 31 (34), pp.4333-42. 〈10.1200/JCO.2012.48.5292〉
Journal of Clinical Oncology, Vol. 31, No 34 (2013) pp. 4333-42
Journal of Clinical Oncology, 2013, 31 (34), pp.4333-42. ⟨10.1200/JCO.2012.48.5292⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2013, 31 (34), pp.4333-42. ⟨10.1200/JCO.2012.48.5292⟩
Purpose The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome in T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c18c2a1ee319431ebce26b579b8aeea
https://hal.archives-ouvertes.fr/hal-00979452
https://hal.archives-ouvertes.fr/hal-00979452
Autor:
Michèle Beau-Faller, Gilbert Massard, Marie Pierre Gaub, Nicolas Meyer, Pierre Oudet, Michèle Legrain, Elisabeth Quoix, Eric Guérin, Anne-Claire Voegeli, Bertrand Mennecier, Anne-Marie Ruppert, Agnès Neuville, Jean-Marie Wihlm
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2008, 3 (4), pp.331-9. ⟨10.1097/JTO.0b013e318168d9d4⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2008, 3 (4), pp.331-9. ⟨10.1097/JTO.0b013e318168d9d4⟩
Introduction Recent clinical success of epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) have raised hopes that targeting other deregulated growth factor signaling, such as the hepatocyte growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb2cadec013248425b450744ea71978b
Autor:
Pierre-Louis Toutain, François Hatey, Pierre J. Ferré, Magali SanCristobal, Agnès Bonnet, Gwenola Tosser-Klopp, Laurence Liaubet, Didier Concordet, Emmanuelle Uro-Coste, Hervé P. Lefebvre
Publikováno v:
Pharmaceutical Research
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research / Pharmaceutical Research (Dordrecht)
Pharmaceutical Research / Pharmaceutical Research (Dordrecht), 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research / Pharmaceutical Research (Dordrecht)
Pharmaceutical Research / Pharmaceutical Research (Dordrecht), 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
International audience; PURPOSE: The purpose of this study is to describe the time course of gene expression in a skeletal muscle local injury induced by an intramuscular (IM) injection, and to compare the dynamics of gene expression with pathologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6b9ba314b202f22100ab07f58a190e6
https://doi.org/10.1007/s11095-007-9266-8
https://doi.org/10.1007/s11095-007-9266-8
Autor:
Pierre Laurent-Puig, Jean-François Emile, Marie-Claude Gorisse, Pascaline Aucouturier, Jean-Philippe Merlio, Florence de Fraipont, Jean-Louis Merlin, Isabelle Durand-Zaleski, Frédérique Nowak, Karen Leroy, Thierry Frebourg, Alain Morel, Hélène Blons, Delphine Le Corre, Gilles Chatellier, Jean-François Côté, Jean-Christophe Sabourin, L'Houcine Ouafik, Etienne Rouleau, Jean-Christophe Boyer, Nathanaël Charrier, Jean-Christophe Pages, Gérard Milano, Patricia de Cremoux
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 7, p e68945 (2013)
PLoS ONE, Public Library of Science, 2013, 8 (7), pp.e68945. ⟨10.1371/journal.pone.0068945⟩
PLoS ONE, 2013, 8 (7), pp.e68945. ⟨10.1371/journal.pone.0068945⟩
PLoS ONE, Public Library of Science, 2013, 8 (7), pp.e68945. 〈10.1371/journal.pone.0068945〉
PLoS ONE, Vol 8, Iss 7, p e68945 (2013)
PLoS ONE, Public Library of Science, 2013, 8 (7), pp.e68945. ⟨10.1371/journal.pone.0068945⟩
PLoS ONE, 2013, 8 (7), pp.e68945. ⟨10.1371/journal.pone.0068945⟩
PLoS ONE, Public Library of Science, 2013, 8 (7), pp.e68945. 〈10.1371/journal.pone.0068945〉
International audience; PURPOSE: Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aee51e27a3ef3933b2dc4c9c734d477
https://pubmed.ncbi.nlm.nih.gov/23935912
https://pubmed.ncbi.nlm.nih.gov/23935912
Autor:
Mazard, Thibault, Causse, Annick, Simony, Joelle, Leconet, Wilhem, Vezzio-Vie, Nadia, Torro, Adeline, Jarlier, Marta, Evrard, Alexandre, Del Rio, Maguy, Assenat, Eric, Martineau, Pierre, Ychou, Marc, Robert, Bruno, Gongora, Celine
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2013, 12 (10), pp.2121-34. ⟨10.1158/1535-7163.MCT-12-0966⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2013, 12 (10), pp.2121-34. ⟨10.1158/1535-7163.MCT-12-0966⟩
International audience; Despite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause of chemotherapy failure. Therefore, new treatment options are needed to improve survival of patients with irinotecan-ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c4ce7a3ac97bd42c8a2db209d6dae01d
https://www.hal.inserm.fr/inserm-00861055
https://www.hal.inserm.fr/inserm-00861055
Autor:
Mazard, Thibault, Causse, Annick, Simony, Joelle, Leconet, Wilhem, Vezzio-Vie, Nadia, Torro, Adeline, Jarlier, Marta, Evrard, Alexandre, del Rio, Maguy, Assenat, Eric, Martineau, Pierre, Ychou, Marc, Robert, Bruno, Gongora, Celine
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2013, 12 (10), pp.2121-34. ⟨10.1158/1535-7163.MCT-12-0966⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2013, 12 (10), pp.2121-34. ⟨10.1158/1535-7163.MCT-12-0966⟩
International audience; Despite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause of chemotherapy failure. Therefore, new treatment options are needed to improve survival of patients with irinotecan-ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1398::c4ce7a3ac97bd42c8a2db209d6dae01d
https://www.hal.inserm.fr/inserm-00861055
https://www.hal.inserm.fr/inserm-00861055
Autor:
Ditte S. Andersen, Valentina Palmerini, Krittalak Chakrabandhu, Julien Colombani, Janine Toggweiler, Michael Röthlisberger, Konrad Basler, Emilie Boone, Marina Mapelli, Pierre Léopold, Anne-Odile Hueber
Publikováno v:
Nature
Nature, Nature Publishing Group, 2015, 522 (7557), pp.482-486. ⟨10.1038/nature14298⟩
Nature, Nature Publishing Group, 2015, 522 (7557), pp.482-6
Nature, Nature Publishing Group, 2015, 522 (7557), pp.482-486. ⟨10.1038/nature14298⟩
Nature, Nature Publishing Group, 2015, 522 (7557), pp.482-6
International audience; Disruption of epithelial polarity is a key event in the acquisition of neoplastic growth. JNK signalling is known to play an important part in driving the malignant progression of many epithelial tumours, although the link bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94c7b12c3ab8699dc2eeacb926afa0c
https://pubmed.ncbi.nlm.nih.gov/25874673
https://pubmed.ncbi.nlm.nih.gov/25874673